These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 15477634

  • 21. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE, El-Ouagari K, Karnon J, Sofrygin O.
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [Abstract] [Full Text] [Related]

  • 22. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
    Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M.
    J Clin Oncol; 2008 Apr 01; 26(10):1671-6. PubMed ID: 18375896
    [Abstract] [Full Text] [Related]

  • 23. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5108-16. PubMed ID: 15998903
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M.
    Clin Cancer Res; 1999 Jul 01; 5(7):1642-9. PubMed ID: 10430063
    [Abstract] [Full Text] [Related]

  • 25. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M.
    Am J Clin Oncol; 2003 Jun 01; 26(3):317-22. PubMed ID: 12796608
    [Abstract] [Full Text] [Related]

  • 26. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G, Verma S, Trudeau M.
    Am J Clin Oncol; 2003 Jun 01; 26(3):289-96. PubMed ID: 12796603
    [Abstract] [Full Text] [Related]

  • 27. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ.
    Strahlenther Onkol; 2002 Feb 01; 178(2):111-3. PubMed ID: 11942036
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D, Thuerlimann B.
    Expert Rev Anticancer Ther; 2006 Jan 01; 6(1):5-10. PubMed ID: 16375638
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 01; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR.
    BJOG; 2003 Dec 01; 110(12):1099-106. PubMed ID: 14664881
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725
    [Abstract] [Full Text] [Related]

  • 38. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU, Vergote I, Sainsbury R.
    Breast J; 2004 Sep 01; 10(3):211-7. PubMed ID: 15125747
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.